Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Citigroup Inc.

Citigroup Inc. increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,141 shares of the medical research company's stock after purchasing an additional 22,788 shares during the quarter. Citigroup Inc. owned approximately 0.46% of Charles River Laboratories International worth $46,513,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund boosted its holdings in shares of Charles River Laboratories International by 1.0% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock valued at $914,000 after buying an additional 45 shares in the last quarter. Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after acquiring an additional 53 shares in the last quarter. American Trust grew its holdings in Charles River Laboratories International by 5.9% in the second quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after purchasing an additional 54 shares during the last quarter. Tortoise Investment Management LLC increased its position in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after purchasing an additional 57 shares in the last quarter. Finally, OLD National Bancorp IN boosted its position in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $5.53 during trading on Monday, reaching $201.30. The stock had a trading volume of 612,650 shares, compared to its average volume of 624,823. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00. The stock has a market cap of $10.29 billion, a PE ratio of 25.18, a PEG ratio of 5.05 and a beta of 1.38. The business has a fifty day moving average price of $194.99 and a 200-day moving average price of $205.65. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business earned $2.72 earnings per share. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has approved a stock buyback plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. Baird R W cut Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 8th. CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating for the company in a research note on Thursday, August 8th. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $214.38.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).